<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02097992</url>
  </required_header>
  <id_info>
    <org_study_id>20120591</org_study_id>
    <secondary_id>DAL-IT-06</secondary_id>
    <nct_id>NCT02097992</nct_id>
  </id_info>
  <brief_title>Effect of Roflumilast on Airway Blood Flow as an Expression of Airway Inflammation in COPD</brief_title>
  <official_title>Effect of Roflumilast on Airway Blood Flow as an Expression of Airway Inflammation in COPD</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Miami</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Forest Laboratories</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Miami</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objectives of the proposed study are to determine 1) the effect of a single dose of
      Roflumilast on airway blood flow (Qaw) (study period 1) and 2) the effect of long-term
      Roflumilast treatment on airway blood flow reactivity delta Qaw)(study period 2) in patients
      with stable COPD who use ICS regularly.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Participants will be enrolled in the study for three months There will be 6 study days
      (visits). The patients will be asked to come to the research laboratory in the morning of the
      study day. They will be instructed to abstain from ingesting alcoholic beverages or using
      PDE5 inhibitors the night before the study, and from consuming coffee or caffeinated drinks
      in the morning of the study day because of their potential acute cardiovascular actions. The
      patients will also be asked not to have a fatty breakfast on the study day to avoid potential
      effects of fat on the absorption of roflumilast.

      The visits will be separated by at least 48 hours. Study period 1: The patients will be
      randomized into two arms: roflumilast or placebo. Qaw will be measured before and at 15, 30,
      60, 120 and 240min in each arm (parallel design) Study period 2: Patients will be randomized
      to either roflumilast for 4 weeks or placebo for 4 weeks and airway blood flow reactivity
      will be measured at the end of the treatment period. The patients will then be taken off
      medication or placebo for 4 weeks and reassigned to the alternate treatment (roflumilast or
      placebo) for 4 weeks and airway blood flow reactivity will be measured after the this
      treatment period (cross-over design).

      The treatments will be administered in a double-blind randomized design, using active
      roflumilast and identically appearing roflumilast placebo provided by Forest.

      Visit 1

      On this visit, a medical history will be obtained from the patients and they will undergo a
      physical examination and complete pulmonary function testing. If they meet entry criteria,
      Qaw will be measured before and 15 min after the inhalation of 180 µg albuterol using a
      spacer (ΔQaw). We have previously shown that vasodilation peaks between 5 and 30 min after
      inhaling this dose of albuterol in healthy non-smokers; in patients with COPD, who exhibit a
      vasodilatory response to inhaled albuterol, the peak effects also occur at the same time as
      in healthy subjects. Since all patients enrolled in the present study will be regular ICS
      users, we expect that all of them will have a vasodilator response to albuterol as previously
      shown.

      Visit 2

      On this day, Qaw will be measured before and at 15, 30, 60,120 and 240 min after the oral
      administration of either 500µg roflumilast or placebo, blinded to patient and investigator
      (acute roflumilast effects).

      Visit 3

      The patients will be given either 500µg roflumilast or placebo (alternate to treatment at
      visit 2) blinded to patient and investigator. One hour later, Qaw will be measured before and
      15 min after the inhalation of 180µg albuterol using a spacer (ΔQaw). Pharmacokinetic studies
      have shown that the geometric mean plasma concentration of roflumilast after a 500µg dose
      peaks at one hour after oral drug administration.

      The patients will then be randomized in a double blind fashion to either roflumilast 500 µg
      or placebo every morning before breakfast. They will be asked to return for a follow up visit
      4 weeks later (visit 4).

      Visit 4

      The patients will not take their morning dose (roflumilast or placebo) on this day. Qaw will
      be measured before and 15 min after the inhalation of 180 µg albuterol using a spacer (ΔQaw).
      The treatment will be discontinued and the patients will be asked to return for visit 5 after
      a 4-week washout period.

      Visit 5

      The protocol of visit 4 will be repeated. The patients will then be started on the alternate
      treatment for 4 weeks: Those on roflumilast between visits 3 and 4 will now be placed on
      placebo, and those on placebo between visits 3 and 4 will be placed on roflumilast. The
      patients will be asked to return for a final visit (visit 6) 4 weeks later.

      Visit 6

      The protocol of visit 4 will be repeated. The patients will then undergo an exit exam and be
      discharged from the study
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 2013</start_date>
  <completion_date type="Actual">July 2015</completion_date>
  <primary_completion_date type="Actual">July 2015</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Airway Blood Flow Reactivity (Delta Qaw)</measure>
    <time_frame>Immediate or 4 weeks</time_frame>
    <description>percentage of change on airway blood flow induced by albuterol.</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">11</enrollment>
  <condition>COPD</condition>
  <arm_group>
    <arm_group_label>SD placebo and MD roflumilast then MD placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive placebo (single dose) followed by a 4 week treatment with 500ug roflumilast daily, followed by a 4 week washout period, followed by a 4 week treatment with placebo daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SD placebo and MD placebo then MD roflumilast</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive placebo (single dose) followed by a 4 week treatment with placebo daily, followed by a 4 week washout period, followed by a 4 week treatment with 500ug roflumilast daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SD roflumilast and MD placebo then MD roflumilast.</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive 500ug roflumilast (single dose) followed by a 4 week treatment with placebo daily, followed by a 4 week washout period, followed by a 4 week treatment with 500ug roflumilast daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SD roflumilast and MD roflumilast then MD placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive 500ug roflumilast (single dose) followed by a 4 week treatment with 500ug roflumilast daily, followed by a 4 week washout period, followed by a 4 week treatment with placebo daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Roflumilast Placebo</intervention_name>
    <description>Placebo pill</description>
    <arm_group_label>SD placebo and MD roflumilast then MD placebo</arm_group_label>
    <arm_group_label>SD placebo and MD placebo then MD roflumilast</arm_group_label>
    <arm_group_label>SD roflumilast and MD placebo then MD roflumilast.</arm_group_label>
    <arm_group_label>SD roflumilast and MD roflumilast then MD placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Roflumilast</intervention_name>
    <description>500 Ug ORAL TABLET</description>
    <arm_group_label>SD placebo and MD roflumilast then MD placebo</arm_group_label>
    <arm_group_label>SD placebo and MD placebo then MD roflumilast</arm_group_label>
    <arm_group_label>SD roflumilast and MD placebo then MD roflumilast.</arm_group_label>
    <arm_group_label>SD roflumilast and MD roflumilast then MD placebo</arm_group_label>
    <other_name>Daliresp</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Twenty-four patients with physician-diagnosed COPD (female and male, current smokers
             or ex-smokers) over the age of 45 years will be recruited for this study.

          -  The patients will have to have a smoking history of at least 10 pack-years, and they
             must have been using an ICS regularly for at least 4 weeks at the time of screening.

          -  Confirmation of the diagnosis of COPD will require the presence of persistent
             exertional dyspnea and a post-bronchodilator FEV1 of less than 80% of predicted and
             FEV1/FVC ratio less than 0.7 (GOLD stage ≥2). At entry into the study, the patients
             will have to be clinically stable; they will be allowed to remain on their regular
             COPD treatment regimen and use a LABA and/or LAMA until 24 hours before, and a SABA
             and/or short-acting muscarinic antagonist (SAMA) until 6 hours before coming to the
             laboratory. If using roflumilast, the subjects will have to discontinue it 4 weeks
             before entering into the study.-

        Exclusion Criteria:

          -  Women of childbearing potential who do not use accepted birth control measures

          -  Pregnant and breast-feeding women.

          -  Use of cardiovascular medications that cannot be held on the study days

          -  Use of oral airway medications or anti-inflammatory agents

          -  Use of supplemental oxygen that cannot be discontinued during the laboratory visit

          -  Subjects with known SABA or roflumilast intolerance

          -  An acute COPD exacerbation within four weeks prior to the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Adam Wanner, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Miami</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Miami Divison of Pulmonary and Critical Care Medicine</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 13, 2014</study_first_submitted>
  <study_first_submitted_qc>March 26, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 27, 2014</study_first_posted>
  <results_first_submitted>March 9, 2017</results_first_submitted>
  <results_first_submitted_qc>July 20, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">August 18, 2017</results_first_posted>
  <last_update_submitted>October 20, 2017</last_update_submitted>
  <last_update_submitted_qc>October 20, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 24, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Miami</investigator_affiliation>
    <investigator_full_name>Adam Wanner</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>COPD</keyword>
  <keyword>airway blood flow</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>SD Placebo and MD Roflumilast Then MD Placebo</title>
          <description>Participants will receive placebo (single dose) followed by a 4 week treatment with 500ug roflumilast daily, followed by a 4 week washout period, followed by a 4 week treatment with placebo daily.</description>
        </group>
        <group group_id="P2">
          <title>SD Placebo and MD Placebo Then MD Roflumilast</title>
          <description>Participants will receive placebo (single dose) followed by a 4 week treatment with placebo daily, followed by a 4 week washout period, followed by a 4 week treatment with 500ug roflumilast daily.</description>
        </group>
        <group group_id="P3">
          <title>SD Roflumilast and MD Placebo Then MD Roflumilast.</title>
          <description>Participants will receive 500ug roflumilast (single dose) followed by a 4 week treatment with placebo daily, followed by a 4 week washout period, followed by a 4 week treatment with 500ug roflumilast daily.</description>
        </group>
        <group group_id="P4">
          <title>SD Roflumilast and MD Roflumilast Then MD Placebo</title>
          <description>Participants will receive 500ug roflumilast (single dose) followed by a 4 week treatment with 500ug roflumilast daily, followed by a 4 week washout period, followed by a 4 week treatment with placebo daily</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Treatment 1 (1 Day)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Treatment 2 (4 Weeks)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Washout (4 Weeks)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Treatment 3 (4 Weeks)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>SD Placebo and MD Roflumilast Then MD Placebo</title>
          <description>Participants will receive placebo (single dose) followed by a 4 week treatment with 500ug roflumilast daily, followed by a 4 week washout period, followed by a 4 week treatment with placebo daily.</description>
        </group>
        <group group_id="B2">
          <title>SD Placebo and MD Placebo Then MD Roflumilast</title>
          <description>Participants will receive placebo (single dose) followed by a 4 week treatment with placebo daily, followed by a 4 week washout period, followed by a 4 week treatment with 500ug roflumilast daily.</description>
        </group>
        <group group_id="B3">
          <title>SD Roflumilast and MD Placebo Then MD Roflumilast.</title>
          <description>Participants will receive 500ug roflumilast (single dose) followed by a 4 week treatment with placebo daily, followed by a 4 week washout period, followed by a 4 week treatment with 500ug roflumilast daily.</description>
        </group>
        <group group_id="B4">
          <title>SD Roflumilast and MD Roflumilast Then MD Placebo</title>
          <description>Participants will receive 500ug roflumilast (single dose) followed by a 4 week treatment with 500ug roflumilast daily, followed by a 4 week washout period, followed by a 4 week treatment with placebo daily</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="2"/>
            <count group_id="B2" value="3"/>
            <count group_id="B3" value="4"/>
            <count group_id="B4" value="2"/>
            <count group_id="B5" value="11"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Airway Blood Flow Reactivity (Delta Qaw)</title>
        <description>percentage of change on airway blood flow induced by albuterol.</description>
        <time_frame>Immediate or 4 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Long Term Multidose Roflumilast or Placebo</title>
            <description>Treatment with 500ug roflumilast or placebo for 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Acute Roflumilast or Placebo</title>
            <description>Treatment with a single dose of 500ug roflumilast or placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Airway Blood Flow Reactivity (Delta Qaw)</title>
          <description>percentage of change on airway blood flow induced by albuterol.</description>
          <units>% of change</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>roflumilast</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.1" spread="6.8"/>
                    <measurement group_id="O2" value="13.7" spread="9.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>placebo</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.9" spread="4.6"/>
                    <measurement group_id="O2" value="15.6" spread="10.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Single Dose Roflumilast</title>
          <description>Participants received a single dose of 500Ug of Roflumilast for one day.</description>
        </group>
        <group group_id="E2">
          <title>Single Dose Placebo</title>
          <description>Participants received a single dose Placebo for one day.</description>
        </group>
        <group group_id="E3">
          <title>Multi-dose Roflumiast</title>
          <description>Participants received a daily dose of 500Ug of Roflumilast for four weeks.</description>
        </group>
        <group group_id="E4">
          <title>Multi-dose Placebo</title>
          <description>Participants received a daily Placebo dose for four weeks</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>3</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>increase of cough</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The number of patients enrolled was lower than expected.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Adam Wanner</name_or_title>
      <organization>University of Miami</organization>
      <phone>(305)243-3045</phone>
      <email>awanner@med.miami.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

